Novozymes establishes biotech campus in Greater Copenhagen

The global bioinnovation leader Novozymes plans a new research centre in Greater Copenhagen with space for 800 employees. The goal is a global hub for biotech R&D.

The world leading biotech company Novozymes, headquartered in Greater Copenhagen, has acquired a 140,000 square metre site in Greater Copenhagen to build a new campus dedicated to biotech research and business development.

“With the location in Lyngby, close to the Technical University of Denmark, our ambition is to create a global hub for biotech research and ground-breaking product development,” said Per Falholt, Executive Vice President for R&D at Novozymes.

Sustainable, energy-efficient solutions

On the new site, as part of campus, Novozymes will build a learning centre including teaching laboratories and a cinema where students and visitors can discover and learn about biology and natural sciences.

Every year, Novozymes reinvests around 14% of its revenue into research, which has resulted in the development of more than 100 new products since the company went public 15 years ago. The products, which are used globally, enable sustainable food production, energy-efficient production and replacement of fossil fuels.


  • The site is located 13 km north of the City of Copenhagen, close to the highway to Elsinore.
  • The site is 140,000 square metres.  The first building phase consists of a 30,000 square metre construction with room for 800 R&D employees.
  • Later expansion is possible to accommodate up to 2,500 employees.